Paper Alert-cum-SfN: Bapineuzumab Published, More AN1792 Presented
Phase 2 clinical trial data for bapineuzumab, Elan/Wyeth’s humanized monoclonal antibody against amyloid-β, were published...
6370 RESULTS
Sort By:
Phase 2 clinical trial data for bapineuzumab, Elan/Wyeth’s humanized monoclonal antibody against amyloid-β, were published...
When scientists compare different centers doing things their way, they see a large variation; even at a single site, variation occurs...
This is a story about how differences among individual centers’ CSF Aβ and tau measurements are posing a serious problem...
Though the ApoE4 variant is the strongest genetic risk factor for late-onset Alzheimer disease, it offers no definitive test...
Designing compounds to fight neurodegenerative disease comes with the additional challenge of making sure they actually reach the brain...
In the past two years, a closer look at epilepsy and Alzheimer disease has revealed some fundamental similarities...
The SfN annual meeting featured a rare convergence of epilepsy and Alzheimer disease researchers at a symposium focused on shared features of these two disorders...
Researchers have identified an unusual gene that keeps a lid on both amyloid production and tau phosphorylation in mouse brain...
A new mouse model of combined Aβ and tau pathology reveals that the pair deliver a one-two punch to mitochondria...
It’s refreshing to hear about studies showing clear convergence between biology, drug action, and behavior, all in the space of a few seconds, no less...
Relationships forged amidst the glitz and glamour of Las Vegas have a reputation for ending badly; the one between the University of Nevada, Reno (UNR), and the Lou Ruvo Brain Institute (LRBI) was apparently no exception...
At a satellite symposium, “Nicotinic Acetylcholine Receptors (nAChRs) as Therapeutic Targets,” clinical discussion of cognitive treatments focused largely on nAChR agonists...
Days before the masses swarmed to the SfN annual meeting, a more intimate assembly of 287 exchanged the latest buzz on nicotinic acetylcholine receptors...
In Alzheimer disease research, focus has recently shifted away from large plaques and toward small oligomers of amyloid as a potential cause of disease...
The window of opportunity for regenerating nerves severed in spinal cord injuries may be more expansive than previously thought...